Biology, Health Care and Football Face Challenges That Simple Explanations Miss

Four debates about biology, health care and sport share a common problem: explanations that reduce complicated systems to a single cause can obscure the forces that shape outcomes. Genes matter, but organisms and environments interact. Medical care can help patients while its business structure adds costs and limits access. A clinic’s confident claims don’t establish that its treatments work. And a high rate of brain disease among former football players demands attention even when researchers still have questions about its clinical effects.

Fifty years after The Selfish Gene

Richard Dawkins’s The Selfish Gene, published in 1976, offered a strikingly clear lens on evolution: organisms could be understood as vehicles through which genes replicate across generations. The book arrived a year after E.O. Wilson’s Sociobiology: A New Synthesis. Both works reflected an ambition to explain biology by identifying its most fundamental parts and giving those parts a central role.

That ambition has scientific appeal. Researchers often make progress by isolating a mechanism and tracing its effects. But a useful starting point can become a misleading account of the whole. Genes shape organisms, yet an organism’s development and survival also depend on its surroundings, interactions with other organisms and processes that cannot be reduced to the transfer of DNA.

A retrospective by Daniel Comfort in Nature argues that the gene-centered view now needs updating. Comfort’s concern is not simply that genes are unimportant. It’s that treating them as the primary actors can make organisms seem passive and encourage a deterministic reading of traits, including aggression. In this account, a gene’s effects appear to dictate the organism, while the organism’s ability to respond to its environment fades from view.

That distinction matters beyond academic terminology. A biological explanation can be used to suggest that complex human behavior is fixed by inheritance. Such claims can lend a scientific gloss to social conclusions that the underlying biology does not support. The source author warns that single-cause accounts of biology have often served eugenic ideas, sometimes openly and sometimes less visibly.

Evolutionary biologists such as Stephen Jay Gould and philosopher Mary Midgley challenged the idea that the gene alone is the unit of selection. The more expansive picture now gaining ground treats heredity and adaptation as processes operating across multiple levels. In that view, organisms are shaped by the world, but they also alter it.

Richard Lewontin’s work helped express this reciprocal relationship: environments influence organisms, and organisms help construct the environments in which they live. That interaction is visible in ecosystems, where species affect one another and can contribute to stability. It also appears in the human body. The microbiome is not inherited in the same direct way as a person’s DNA, yet the body depends on its microbial communities.

Epigenetic changes add another layer. Molecular modifications can affect how genes are expressed without changing the DNA sequence itself, and some evidence suggests that these changes can be inherited. These mechanisms do not make genes irrelevant. They make the route from genes to traits less direct than a simple gene-centered account might imply.

Scott F. Gilbert and David W. Pfennig’s Eco-Evo-Devo: The Environmental Regulation of Development, Health, and Evolution is recommended as a recent treatment of these connections. The source author has not read it, but expects its approach to have a broad reach, including possible relevance to the basic biology of cancer. That expectation is prospective, not a finding about the book’s impact.

The practical takeaway is to be wary when a complicated biological outcome is assigned one controlling cause. Genes are indispensable to life, but no single level of explanation captures all the ways organisms develop, respond and interact. The wider view is still being built; its value lies in asking what a narrow account leaves out.

The business structure behind health care

The debate over “Big Medicine” turns on a different kind of reduction: treating health care primarily as a market commodity. Arnold Relman, a physician, researcher and former editor of The New England Journal of Medicine, spent much of his career warning that care in the United States was becoming a profit-driven industry. His concern was that access would increasingly track a person’s ability to pay rather than medical need.

Relman became editor of the journal in 1977. The publication grew in prominence under his leadership, publishing research alongside analysis of ethical and policy questions in medicine. In a landmark 1980 article, “The New Medical-Industrial Complex,” he argued that commercial incentives were reshaping the health system.

The figures in the obituary that revisited his argument are stark: the United States spends about twice as much per person on health care as other advanced countries, yet millions of people have no or inadequate coverage. The account attributes much of the spending to costs such as overhead, profits and tests that may not be medically necessary. Spending more, in this telling, has not translated into broad access.

Relman proposed two linked changes. He favored a single-payer financing system, with Medicare offered as a model, and a nonprofit delivery system built around groups of doctors paid salaries within set budgets. His position was that financing and delivery needed to work together: changing who pays would not alone resolve the incentives created by profit-oriented care.

He also argued that the Affordable Care Act could ultimately unravel without fundamental reform. He recognized that it expanded access, but believed it left the private insurance industry and profit-oriented delivery model in place. In his view, that could lead either to rapidly rising costs or to benefits weakened by high deductibles and copayments.

The source author says the problems Relman identified have worsened over the past twelve years and describes a long-held expectation that the United States would eventually repair its health system as misplaced. The essay’s judgment is bleak: meaningful change may come only after the system reaches a breaking point. That is an opinion about the prospects for change, not a forecast supported by a specific timetable.

Medical students may become part of the response, the author suggests, though the influence of large health care institutions can be difficult to resist. For patients, the stakes are concrete: whether care is available when needed, how much it costs, and whether the services provided reflect medical need. For clinicians, the challenge is practicing within a structure whose financial incentives may not align with patient care.

Relman’s argument remains relevant because it asks readers to look past the total amount spent and examine how money moves through the system. The key questions are who can obtain care, which services generate revenue, and how payment arrangements affect clinical choices. The source offers no new data to settle those questions, but it frames them as the central test of whether the system serves patients.

Claims and evidence at a Swiss clinic

A report by D.T. Max in The New Yorker examines Thomas Rau, a Swiss physician who describes his approach as “biological” medicine. Rau says the body’s defenses should be strengthened rather than focusing only on a particular disease. He criticizes conventional specialists as too narrowly focused and treats patients with conditions he calls “unclear,” including long COVID and chronic fatigue syndrome.

Rau operates BioMed, a clinic with an adjoining hotel in Schwellbrunn, Switzerland. Patients may stay for several weeks and spend tens of thousands of dollars. He estimates that eighty per cent of patients with the “unclear” conditions he treats leave “massively improved.” That is his estimate, as reported by Max; the source does not provide controlled research to confirm it.

A central part of Rau’s approach is dark-field microscopy. He examines a drop of blood over time, interpreting patterns such as clumping or “stacked rings” as signs of toxins or inflammation. He has described the method as a fast way to draw conclusions about dynamic processes in the body. Yet the source author disputes the biological basis for those readings.

Red blood cells can form rouleaux, or stacked arrangements, when the fluid portion of blood changes for a range of reasons. The author emphasizes that this finding is nonspecific: it may indicate that something is out of balance, but does not identify a cause. The author also notes that red blood cells are not motile. White blood cells are the blood’s motile cells; red cells may shift through Brownian motion, but that is not purposeful movement.

That difference undercuts the claim that watching red blood cells move or clump can deliver a broad diagnosis. The source author argues that hematologists would reject the idea that this technique is an especially informative measure of dynamic processes in the body. A visual pattern may look persuasive to a patient, but an interpretation still needs a validated link to a condition and evidence that it can guide effective care.

Rau’s treatments include colon hydrotherapy, ozone infused into the blood and hyperthermia, in which a patient lies on a bed heated with infrared-A radiation. The clinic’s account presents the heat treatment as a way to mimic fever and supposedly shrink tumors. Rau has said he is unconcerned by the lack of studies confirming that the clinic’s treatments work, telling Max: “I pay a lot of taxes. I pay scientists’ salaries.” Paying researchers, however, is not itself evidence that a treatment is effective.

The source author describes colon hydrotherapy as little more than an enema and says ozone infusion is hazardous, with no known benefit and possible harm to red blood cells and blood vessel linings. The author also rejects the claim that infrared light shrinks tumors. Those are the author’s medical assessments; the reported account does not establish that BioMed’s interventions have been tested in a way that demonstrates patient benefit.

People with persistent symptoms and no clear diagnosis can be especially drawn to confident explanations. Rau’s focus on “unclear” conditions also makes improvement difficult to assess without clear definitions and systematic follow-up. A patient’s experience matters, but it cannot by itself show whether a treatment caused the change, how often it helps, or what risks it carries.

The clinic’s comfortable setting and high prices are part of the story, but they don’t establish either success or failure. Max’s report leaves the outcome unresolved. The broader issue is familiar: alternative and functional medicine practices can attract patients who feel conventional care has not answered their needs. In such cases, the claims deserve scrutiny on their evidence and risks, especially when the treatments are invasive or costly.

Football’s brain health question

The strongest numbers in the source concern former National Football League players and chronic traumatic encephalopathy (CTE), a disease associated with symptoms including mood swings and dementia. CTE can currently be diagnosed only by examining the brain after death. That makes its prevalence among current or former players difficult to measure directly, because people who donate their brains may differ from those who do not.

A study in JAMA Network Open analyzed records for 2,362 former NFL players who died between 2008 and 2023. They had played in the league for an average of 5.1 years, with 971, or 41.1%, aged 80 or older at death. Of the 396 brain donors, 387 were included in the reported donor analysis; 362 of those 387, or 93.5%, had CTE.

That donor rate cannot be treated as the rate for all former players. Brain donation may be more likely when a player had cognitive symptoms or a family had reason to suspect brain disease. To address that selection bias, the researchers estimated how much more likely donation was among people with CTE and adjusted the donor findings accordingly.

Their bias-adjusted estimate puts CTE prevalence at death among the study population at 74.5%, with a 95% confidence interval of 69.6% to 78.3%. A conservative lower-bound analysis estimated 63.7%, with a 95% confidence interval of 57.2% to 68.9%. The researchers also estimated that 27.2% of the population had a history of dementia during life, with a 95% confidence interval of 22.6% to 31.6%.

The study’s conclusion is measured: selection bias materially raises donor-based estimates, but is unlikely to explain the high prevalence of CTE pathology in the group. Further research is needed to understand the disease’s clinical impact. The distinction matters. The findings concern former NFL players who had died, and they do not establish the prevalence of CTE in all players or explain each person’s symptoms.

For context, the article cites a rate below 1% in brains held by community-based brain banks. That comparison is striking, but the groups and donation pathways differ. Yorghos Tripodis, the study’s senior author and a Boston University biostatistics professor, said no other environmental or occupational exposure studied is known to have raised dementia risk at death by a comparable amount.

The source author argues that repeated acceleration of the brain, causing it to strike the skull, offers a mechanism for cumulative injury. The study itself is observational, and the author’s expectation that further research will establish a causal path goes beyond its reported results. Still, the combination of a plausible mechanism and a high adjusted prevalence makes the findings difficult to dismiss as a donor sample artifact alone.

The consequences extend beyond professional play. College football generates substantial sums, and players can now receive large payments through name, image and likeness arrangements. The source cites a quarterback earning $5 million a year and more. The author supports players receiving compensation, while questioning whether colleges can justify the long-term health risks to athletes in a sport whose commercial value depends on continued participation.

There are also signs of a possible cultural shift. The author’s informal conversations with young mothers suggest reluctance to let sons play, though the anecdote is not representative evidence. A personal connection sharpens the point: a former high school coach who later played five years as an NFL defensive back died last year, and his daughter requested contributions to Boston University’s CTE Research Center. The source author says football may wither if fewer young people enter the sport.

That outcome is uncertain, as is the future of the sport’s financing and public appeal. The near-term issue is whether families, schools and athletic programs treat brain health as a material cost of participation. The study’s estimates do not settle every clinical question, but they make one conclusion hard to avoid: the burden of CTE among deceased former NFL players appears substantial, and the unanswered questions concern its reach and effects, not whether the signal deserves attention.